TAPE/#

Speaker

Comments

TAPE 45, A

003

Chair Monnes Anderson

Calls the meeting to order at 1:03 p.m.  Opens public hearing on SB 962.

SB 962 – PUBLIC HEARING

010

Rep. Vicki Berger

House District 20.  Testifies in support of SB 962.

035

Rick Berkobien

Committee Administrator.  Explains the bill and introduces the -1 amendments (EXHIBIT A).

050

Sarah Doll

Program Director, Oregon Environmental Council.  Submits and presents written testimony in support of SB 962 (EXHIBIT B).

070

Chair Monnes Anderson

Asks where the report is regarding the study performed on dust.

071

Doll

Answers question.  Continues testifying in support of SB 962.

095

Chair Monnes Anderson

Asks to clarify what chemicals Europe has banned.

096

Doll

Answers question.

100

Wendy Marich

Citizen, Oregon.  Testifies in support of SB 962.

129

Chair Monnes Anderson

Stands the committee at ease.

135

Chair Monnes Anderson

Reconvenes the meeting.

140

Jim Marquee

American Chemistry Council.  Introduces Susan Landry and Ray Dawson.

150

Susan Landry

Advisor, Fire Safety & Advocacy, Albemarle Corporation.  Submits and presents written testimony in opposition to SB 962 (EXHIBIT C), a PowerPoint presentation on “Deca-BDE Regulatory and Environmental Issues” (EXHIBIT D) and a fact sheet about Flame Retardants (EXHIBIT E).

160

Landry

Continues discussing PowerPoint presentation on Deca-BDE Regulatory & Environmental Issues.

200

Landry

Continues discussing PowerPoint presentation on Deca-BDE Regulatory & Environmental Issues.

255

Landry

Summarizes and concludes.

260

Ray Dawson

Bromine Science and Environmental Forum, Washington D.C. Continues on page 13 of the PowerPoint presentation of EXHIBIT D.  Submits written testimony in opposition to SB 962 (EXHIBIT F) and an informational packet on Polybrominated Diphenyl Ethers (PBDEs) on behalf of Donald Moulds, Director, Senate Office of Research, Sacramento, California (EXHIBIT G).

298

Chair Monnes Anderson

Asks Dawson to comment on previously banned chemicals in Europe.

300

Dawson

Defers to later in the presentation.  Continues discussing PowerPoint presentation on Deca-BDE Regulatory & Environmental Issues.

330

Chair Monnes Anderson

Asks to clarify why testing is mostly being performed in Europe.

335

Dawson

Provides explanation.  Continues discussing PowerPoint presentation on Deca-BDE Regulatory & Environmental Issues.

385

Dawson

Continues discussing PowerPoint presentation on Deca-BDE Regulatory & Environmental Issues.

405

Chair Monnes Anderson

Asks Dawson to comment on Penta and Octa chemicals.

410

Dawson

Provides explanation.  Continues discussing PowerPoint presentation on Deca-BDE Regulatory & Environmental Issues.

TAPE 46, A

005

Sen. Kruse

Asks Marquee if he would be supportive of the bill with the -1 amendments.

010

Marquee

Discusses why they oppose the bill overall.

025

Sen. Kruse

Thanks the panel for the information.

040

Jennifer Kimball

Citizen, Marion County, Oregon.  Testifies in support of SB 962.

060

Janie Huff-Slankard

Pediatric Nurse Practitioner.  Oregon Pediatric Nurse Practitioner Association.  National Association for Pediatric Nurse Practitioners.  The American Academy of Pediatrics.  Submits and presents written testimony in support of SB 962 (EXHIBIT H).

070

Chair Monnes Anderson

Asks for studies that Huff-Slankard refers to.

071

Huff-Slankard

Offers to return information to the committee.  Continues to review testimony in support of SB 962.

125

Kim Hooper

Ph.D., Hazardous Materials Laboratory, Berkeley, California.  Submits and presents PowerPoint presentation in support of SB 962 (EXHIBIT I).

175

Chair Monnes Anderson

Asks to verify and explain studies performed as discussed in his testimony.

177

Hooper

Explains.  Continues testimony.

207

Chair Monnes Anderson

Asks to clarify that Deca breaks down rapidly.

208

Hooper

Answer, yes.  Explains.

228

Chair Monnes Anderson

Asks if a study has been performed with Deca broken down on mice.

230

Hooper

Answers question. Continues to discuss PowerPoint presentation on “Deca-BDE: Why are we concerned?”

280

Chair Monnes Anderson

Asks to comment on Europe’s statement two days prior regarding Deca.

283

Hooper

Defers answer to later in presentation. Continues presentation.

325

Chair Monnes Anderson

Asks why California has not banned Deca.

327

Hooper

Speculates.

335

Sen. Morrisette

Asks if Washington has banned Deca.

336

Hooper

Answers question.

337

Sen. Morrisette

Asks if other states have banned Deca.

340

Hooper

States that he does not know.  Discusses how Deca enters into the human system.

350

Catherine Thomasson

Physician, Internal Medicine.  President, Oregon Chapter of Physicians for Social Responsibility.  States that Maine has banned Deca.  Submits informational packet on Deca-BDE in support of SB 962 (EXHIBIT J).  Reviews PowerPoint presentation about Deca-BDE.

438

Chair Monnes Anderson

Asks to clarify that the statistics Thomasson refers to include polybrominated diphenyl ethers (PBDEs).

440

Thomasson

Responds.

TAPE 45, B

006

Chair Monnes Anderson

Asks if Deca-BDE is part of a Polychlorinated Biphenyls (PCB).

080

Thomasson

Responds.

010

Sen. Morrisette

Asks if PBDEs is the same as Deca-BDE.

012

Thomasson

Answers question.

014

Sen. Morrisette

Comments on the three categories of chemicals in the bill and remarks that there has been an amendment introduced to exclude Deca from the bill. Asks to the clarify article that he read in the Oregonian.

020

Thomasson

Responds.

021

Hooper

Adds further explanation.

022

Sen. Morrisette

Refers to same article in the Oregonian.  Asks what the article means by “restrictions of the chemicals” of PBDEs.

023

Thomasson

Clarifies that only Deca is banned in Maine.

025

Chair Monnes Anderson

States that it will be addressed later.

028

Thomasson

Comments that states have been phasing out the chemicals.  Continues reviewing PowerPoint presentation on Deca-BDE.

043

Chair Monnes Anderson

Clarifies the study that Thomasson referred to.

045

Thomasson

Answers question.

046

Chair Monnes Anderson

States that she would interested if blind studies were performed.

047

Hooper

Clarifies that controlled studies were performed.  Elaborates.

053

Thomasson

Continues reviewing PowerPoint presentation on Deca-BDE.  Discusses alternatives.

080

Chair Monnes Anderson

Asks if Thomasson is aware of information from a study that takes Deca from the 2006 ban.

083

Thomasson

Discusses her understanding.  Continues discussing alternatives.

110

Chair Monnes Anderson

Asks if much research has been performed on ammonium and aluminum.

112

Thomasson

Defers answer to later in the presentation.

150

Thomasson

Summarizes and concludes.

165

Kathleen Diane Drum

Oregon Nurses Association (ONA).  Member, Health Policy Cabinet Public Health Nurse.  Maternal-Child Health.  Submits and presents written testimony in support of SB 962 (EXHIBIT K) and a report on “Neurobehavioral Derangements in Adult Mice Receiving Decabrominated Diphenyl Ether (PBDE 209) during a Defined Period of Neonatal Brain Development” (EXHIBIT L).

215

Drum

Continues to testify in support of SB 962.

265

Drum

Summarizes and concludes.

290

Rhett Lawrence

Environmental Advocate, Oregon State Public Interest Research Group (OSPIRG).  Submits and presents written testimony in support of SB 962 (EXHIBIT M).

340

Drum

Comments that mothers in Oregon have the highest levels of PBDEs in their breast milk in the nation and in the world.

360

Myrna Soule

Hearing Disability Association of Oregon.  Testifies in support of SB 962.

420

Amelia Psmythe

Executive Director, Nursing Mothers Counsel of Oregon.  Submits and presents written testimony regarding SB 962 (EXHIBIT N).

TAPE 46, B

010

Gail Shibley

Administrator, Health Services, Office of Public Health Systems, Oregon Department of Human Services.  Submits and presents written testimony with a neutral position on SB 962 (EXHIBIT O).

018

Sen. Kruse

States that the legislature should proceed with caution.  Comments on a book written by Rachael Green called Silent Spring.

The following material is submitted for the record without public testimony:

Bob Livingston

Legislative Director, Oregon State Fire Fighters Council.  Submits written testimony in support of SB 962 (EXHIBIT P).

035

Chair Monnes Anderson

Closes the public hearing on SB 962 and opens a public hearing on SB 783 and SB 784.

SB 783, SB 784 – PUBLIC HEARING

040

Rick Berkobien

Committee Administrator.  Explains SB 783 and SB 784 and introduces the -1 amendments to SB 783 (EXHIBIT Q) and the -1 amendments to SB 784 (EXHIBIT R).

050

Sen. Bill Morrisette

Senate District 6.  Testifies in support of SB 783 and SB 784.

085

Deborah Turner

Chairperson, Government and Public Affairs Committee, Oregon State Assembly of the Association of Surgical Technologies, Inc.  Submits and presents written testimony in support of SB 784 (EXHIBIT S) and in support of SB 783 (EXHIBIT T).

155

Chair Monnes Anderson

Asks Turner if she assisted in Sen. Morrisette’s operation.

157

Turner

Responds, yes.

162

Sen. Morrisette

Comments on his procedure.

175

Adam Perryman

President, Oregon State Assembly of the Association of Surgical Technologists.  Submits and presents written testimony in support of SB 783 and SB 784 (EXHIBIT U).

225

Perryman

Continues to testify in support of SB 783 and SB 784.

285

Turner

Testifies in support of SB 783.

355

Chair Monnes Anderson

Closes the public hearing on SB 783 and SB 784.  Adjourns meeting at 2:56 p.m.